Chronic Sinusitis

Back

Background

Chronic sinusitis is one of the more prevalent chronic illnesses in the United States, affecting persons of all age groups (see Epidemiology). It is an inflammatory process that involves the paranasal sinuses and persists for 12 weeks or longer (see Pathophysiology). The literature has supported that chronic sinusitis is almost always accompanied by concurrent nasal airway inflammation and is often preceded by rhinitis symptoms; thus, the term chronic rhinosinusitis (CRS) has evolved to more accurately describe this condition.

CRS may manifest as one of three major clinical syndromes: CRS without nasal polyps, CRS with nasal polyps, or allergic fungal rhinosinusitis. These classifications possess a great deal of therapeutic significance.

Most cases of chronic sinusitis are continuations of unresolved acute sinusitis; however, chronic sinusitis usually manifests differently from acute sinusitis. Symptoms of chronic sinusitis include nasal stuffiness, postnasal drip, facial fullness, and malaise. (See Clinical Presentation.)

Chronic sinusitis may be noninfectious and related to allergy, cystic fibrosis, gastroesophageal reflux, or exposure to environmental pollutants.[1, 2] Allergic rhinitis, nonallergic rhinitis, anatomic obstruction in the ostiomeatal complex, and immunologic disorders are known risk factors for chronic sinusitis. (See Etiology.)

Medical therapy is directed toward controlling predisposing factors, treating concomitant infections, reducing edema of sinus tissues, and facilitating the drainage of sinus secretions. The goal in surgical treatment is to reestablish sinus ventilation and to correct mucosal opposition in order to restore the mucociliary clearance system. Surgery strives to restore the functional integrity of the inflamed mucosal lining. (See Treatment and Management and Medication.)

Definition of chronic rhinosinusitis

In 1996, the American Academy of Otolaryngology-Head & Neck Surgery multidisciplinary Rhinosinusitis Task Force (RTF) defined adult rhinosinusitis diagnostic criteria.[3] Major factors included facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, hyposmia or anosmia, purulence in nasal cavity, and fever. In 2003, the RTF’s definition was amended to require confirmatory radiographic or nasal endoscopic or physical examination findings in addition to suggestive history.[4, 5] (See Clinical Presentation.)

Anatomy

Knowledge of the anatomy of paranasal sinuses is essential for understanding the pathophysiology and management of chronic sinusitis. The 4 pairs of paranasal sinuses are lined with ciliated, pseudostratified columnar epithelium. Goblet cells are interspersed among the columnar cells. The mucosa is attached directly to the bone. Involvement of the surrounding bone and further extension of the infection into the orbital and intracranial compartments can result from inadequate treatment of sinusitis and specific types of sinusitis (eg, fungal sinusitis).

The maxillary, frontal, and anterior ethmoid sinuses drain through their ostia located at the ostiomeatal complex lying lateral to the middle turbinate within the middle meatus. The posterior ethmoid and sphenoid sinuses open into the superior meatus and sphenoethmoid recess, respectively. The maxillary ostium is connected to the nasal cavity by a narrow tubular passage called the infundibulum, located at the highest part of the sinus; hence, drainage from the maxillary sinus flows against gravity via mucociliary clearance. Because the floor of the maxillary sinus is the tooth-bearing part of the maxilla, dental infections can easily extend to the maxillary sinus. Although the nasal cavity is usually colonized with bacteria, the sinuses are typically sterile.

Pathophysiology

Stasis of secretions inside the sinuses can be triggered by (1) mechanical obstruction at the ostiomeatal complex due to anatomic factors or (2) mucosal edema caused by various etiologies (eg, acute viral or allergic rhinitis).

Mucous stagnation in the sinus forms a rich medium for the growth of various pathogens. The early stage of sinusitis is often a viral infection that generally lasts up to 10 days and that completely resolves in 99% of cases. However, a small number of patients may develop a secondary acute bacterial infection that is generally caused by aerobic bacteria (ie, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis). Initially, the resulting acute sinusitis involves only one type of aerobic bacteria. With persistence of the infection, mixed flora, anaerobic organisms, and, occasionally, fungus[6] contributes to the pathogenesis, with anaerobic bacteria of oral flora origin often eventually predominating. In one study, these bacterial changes were demonstrated with repeated endoscopic aspiration in patients with maxillary sinusitis.[7] Most cases of chronic sinusitis are due to acute sinusitis that either is untreated or does not respond to treatment.

The role of bacteria in the pathogenesis of chronic sinusitis is currently being reassessed. Repeated and persistent sinus infections can develop in persons with severe acquired or congenital immunodeficiency states or cystic fibrosis.

Current thinking supports the concept that chronic rhinosinusitis (CRS) is predominantly a multifactorial inflammatory disease. Confounding factors that may contribute to inflammation include the following:

All of these factors can play a role in disruption of the intrinsic mucociliary transport system. This is because an alteration in sinus ostia patency, ciliary function, or the quality of secretions leads to stagnation of secretions, decreased pH levels, and lowered oxygen tension within the sinus. These changes create a favorable environment for bacterial growth that, in turn, further contributes to increased mucosal inflammation.

Etiology

The etiology of chronic sinusitis is multifactorial. The interaction between many systemic, local host, and environmental factors contribute to sinus inflammation and to the pathophysiology of the disease. Systemic factors include genetic diseases such as cystic fibrosis, conditions that cause immunodeficiency, autoimmune disease, idiopathic conditions such as Samter triad (aspirin-exacerbated respiratory disease), and acid reflux. Local host factors include sinonasal anatomic abnormalities, iatrogenic conditions such as scarring due to prior sinus surgery, neoplasm, or the presence of a foreign body, among others. Possible environmental factors that may contribute to the condition include the presence of biofilms and bacterial infection, as well as fungal infection, allergy, environmental pollutants, and smoking.

Increasing evidence shows that biofilms are critical to the pathophysiology of chronic infections including chronic sinusitis. Recent advances in methods for biofilm identification and molecular biology offer new insights into the role of biofilms in chronic sinusitis.[11]

Currently, etiologic studies of sinusitis are increasingly focusing on ostiomeatal obstruction, allergies, polyps, occult and subtle immunodeficiency states, and dental diseases. Microorganisms are more often recognized as secondary invaders. Any disease process or toxin that affects cilia has a negative effect on CRS.

Bacterial involvement

The bacteria presumed to be involved in CRS differ from those involved in acute rhinosinusitis. The following bacteria have been reported in samples obtained through endoscopy or sinus puncture in patients with chronic sinusitis.

In contrast with the well-established roles of microbes in the etiology of acute sinusitis, the exact roles of all of these microbes in the etiology of chronic sinusitis are uncertain. Various researchers disagree on the microbial etiology of chronic sinusitis. Much of the disagreement may be explained by methodology. Studies that have used adequate methods for recovery of anaerobes have demonstrated their prominence in chronic sinusitis, while those that did not use such methods have failed to recover them. When proper techniques are used, anaerobic bacteria can be recovered in 50-70% of specimens.[14] The variable growth of microbes in samples may also be due to prior exposure of various broad-spectrum antibiotics in patients involved in the studies.

Jyonouchi et al successfully induced chronic sinusitis in rabbits via intrasinus inoculation of Bacteroides fragilis. The authors subsequently identified immunoglobulin G (IgG) antibodies against this organism in the infected animals.[16] In addition, IgG antibodies to anaerobic organisms have been observed in patients with chronic sinusitis.[17] These findings further support a role for anaerobes in chronic sinusitis.

Microbiologic studies of chronic sinusitis often show that the infection is polymicrobial, with isolation of 1-6 isolates per specimen.[13] .The microbial flora of chronic sinusitis is affected by previous antibiotic administration, past vaccinations, and the presence of normal flora that can suppress the emergence of pathogenic species.

In some cases, the baseline chronic sinusitis worsens suddenly or causes new symptoms. This acute exacerbation of chronic sinusitis is often polymicrobial as well, with anaerobic bacteria predominating. However, aerobic bacteria that are usually associated with acute sinusitis (eg, S pneumoniae, H influenzae,M catarrhalis) may emerge.[18]

S aureus infection is associated with the development of persistent severe inflammatory disease of the upper airway, including chronic sinusitis with nasal polyps.[19]

Gram-negative facultative and aerobic bacteria, including P aeruginosa, are more often isolated in patients with chronic sinusitis who have undergone endoscopic sinus surgery.[20]

Fungal involvement

The following fungi have been reported in samples obtained with endoscopy or sinus puncture in patients with chronic sinusitis[21] :

To see complete information on Fungal Sinusitis, please go to the main article by clicking here.

Risk factors

The following conditions and risk factors predispose patients to the development of chronic sinusitis:

Epidemiology

Chronic sinusitis is one of the more prevalent chronic illnesses in the United States, affecting persons of all age groups. The overall prevalence of CRS in the United States is 146 per 1000 population. For unknown reasons, the incidence of this disease appears to be increasing yearly. This results in a conservative estimate of 18-22 million physician visits in the United States each year and a direct treatment cost of $3.4-5 billion annually.[23] Chronic sinusitis is the fifth most common disease treated with antibiotics. Up to 64% of patients with AIDS develop chronic sinusitis.[24]

International prevalence

Chronic sinusitis is a common disease worldwide, particularly in places with high levels of atmospheric pollution. In the Northern Hemisphere, damp temperate climates along with higher concentrations of pollens are associated with a higher prevalence of chronic sinusitis.

Rhinosinusitis in children

Rhinosinusitis is more common in the pediatric population because this term includes both acute and chronic infection and both viral and bacterial disease. This is likely secondary to an increased frequency of exposure to upper respiratory tract infections in the pediatric population.

Prognosis

Because of its persistent nature, chronic sinusitis can become a significant cause of morbidity. If left untreated, it can reduce the quality of life and the productivity of the affected person.

Chronic sinusitis is associated with exacerbation of asthma and serious complications such as brain abscess and meningitis, which can produce significant morbidity and mortality.

Early and aggressive medical treatment for chronic sinusitis typically results in satisfactory outcomes. Functional endoscopic sinus surgery (FESS) restores sinus health with complete or moderate relief of symptoms in 80-90% of patients with recurrent or medically unresponsive chronic sinusitis. (See Treatment and Management.)

Chronic sinusitis is rarely life threatening, although serious complications can occur because of the proximity to the orbit and cranial cavity. Approximately 75% of all orbital infections are directly related to sinusitis. Intracranial complications remain comparatively rare, with 3.7-10% of intracranial infections related to sinusitis.[25] (See Complications.)

History

Patient history is extremely important in chronic rhinosinusitis (CRS) because of the broad overlap between sinus symptoms and other disease processes, as well as poor correlation between symptoms and endoscopic and radiographic findings.

Chronic sinusitis manifests more subtly than acute sinusitis. However, it may start suddenly, as an upper respiratory tract infection or acute sinusitis that does not resolve, or emerge slowly and insidiously over months or years. At times, the initial symptoms may be acute in nature. Unless an appropriate history is taken, the diagnosis may be missed. The typical symptoms of acute sinusitis—fever and facial pain—are usually absent in chronic sinusitis. Fever, when present, may be low grade.

Patients with chronic sinusitis may present with the following symptoms:

In pediatric settings, halitosis is reported more commonly by parents of younger children. Nasal obstruction with mouth breathing and associated sore throat may be present. In some individuals with chronic sinusitis, parents may note occasional and painless morning eye swelling. Older children may complain of loss of taste due to associated nasal obstruction and anosmia. Nocturnal symptoms may include snoring and coughing due to associated postnasal drip.

The patient history should focus on the following key factors, beginning with consideration of major and minor diagnostic criteria:

Physical Examination

Physical examination in patients with chronic sinusitis may reveal various findings. It should include a complete head and neck examination (lymphadenopathy) to confirm the diagnosis and to rule out more serious disorders.

Sinus palpation is performed to evaluate tenderness or swelling. Pain or tenderness on palpation over frontal or maxillary sinuses may be noted. Transillumination of maxillary or frontal sinuses may be useful; it lacks sensitivity but may have value in experienced hands.

An oral cavity and oropharynx examination is used to evaluate the integrity of the palate and the condition of dentition and to look for evidence of postnasal drip. Oropharyngeal erythema and purulent secretions may be noted. Dental caries may be present.

Anterior rhinoscopy, with the use of a nasal speculum, is used to evaluate the condition of the nasal mucosa and to look for purulent drainage or evidence of polyps or other nasal masses. Other contributing factors to CRS that can be evaluated are nasal septal deviation and turbinate hypertrophy. The nasal examination should be carried out both before and after the use of a topical decongestant.

The nasal examination can be supplemented with the use of nasal endoscopy (if available) and CT scanning. Endoscopic (rhinoscopic) examination findings include the following:

An endoscopic view of the nasal cavity can be seen below.



View Image

Endoscopic view right nasal cavity; lacrimal bone (L), uncinate process (U), ethmoid bulla (B), middle turbinate (MT), nasal septum (S).

Ear examination for the presence of middle ear fluid that may be the sign of a mass in the nasopharynx is indicated.

Ocular examination for spread of disease to the orbit and function of ocular musculature is indicated. Ophthalmic manifestations include the following:

Laryngeal examination is used to look for other confounding upper airway pathology including laryngeal-pharyngeal reflux (LPR). Lung examination is performed to determine if coexisting lower airway disease is present.

Cranial nerve examination is performed to look for underlying sinus malignancy or neurological disorder.

Manifestations of fungal sinusitis

Fungal sinusitis can manifest in different ways.[27] Unlike acute invasive fungal sinusitis, which is observed in patients who are immunosuppressed or who have diabetes, chronic fungal sinusitis is usually observed in immunocompetent patients. Mycetomas or fungus balls may be asymptomatic or may manifest as chronic sinusitis. Allergic fungal sinusitis usually manifests as nasal polyps and allergic sinusitis. Fungal elements in the sinuses are the inciting allergens.

Diagnostic Criteria

In 1996, the American Academy of Otolaryngology-Head & Neck Surgery convened a multidisciplinary Rhinosinusitis Task Force (RTF). This group defined adult rhinosinusitis diagnostic criteria.[3] These 1996 diagnostic criteria required 2 or more major factors or 1 major factor and 2 minor factors for the diagnosis of rhinosinusitis.

Major factors included facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, hyposmia or anosmia, purulence in nasal cavity, and fever (for acute rhinosinusitis only).

Minor factors were defined as headache, fever (for CRS), halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness. Of note, facial pain requires another major factor associated with it for diagnosis (facial pain plus 2 minor factors is not deemed sufficient for diagnosis of rhinosinusitis).

In 2003, the RTF’s definition was amended to require confirmatory radiographic or nasal endoscopic or physical examination findings in addition to suggestive history.[4] The 2003 diagnostic criteria for CRS require the above criteria for longer than 12 weeks or more than 12 weeks of physical findings. In addition, one of the following signs of inflammation must be present:

Imaging modalities confirming the diagnosis include the following:

OR

In general, plain radiography has low sensitivity and specificity. CT scanning is considered the imaging standard for evaluation of chronic sinusitis.[28]

The latest executive summary on adult sinusitis has altered the definition for CRS to read 12 weeks or longer of 2 or more of the following symptoms:[29]

In addition, inflammation must be documented by demonstrating one of the following:

This is in contrast to recurrent acute sinusitis, which is present when 4 or more episodes per year of acute bacterial rhinosinusitis without signs and symptoms of rhinosinusitis between episodes.

Complications

The most serious complications of chronic sinusitis are neurological. Among these include subdural empyema, meningitis, venous sinus thrombosis, orbital cellulitis, and epidural abscess.[30]

Approach Considerations

Always consider serious underlying conditions, such as tumors and immunodeficiency states, in the workup of chronic sinusitis. In general, plain radiography has low sensitivity and specificity. CT scanning is considered the imaging standard for evaluation of chronic sinusitis. Routine blood cell counts and sedimentation rates are generally unhelpful; however, these may be elevated in patients with fever.

The cornerstone in the diagnostic workup of chronic sinusitis is the radiologic examination. Nasal endoscopy is recommended in most cases prior to obtaining imaging because it demonstrates the condition of the nasal mucosa and evaluates for purulent drainage.

Radiographic findings in individuals with chronic sinusitis may demonstrate osteoblastic response in the affected sinus walls, mucoperiosteal thickening, opacification of sinus cavity, and even reduction of cavity size. Younger children with persistent respiratory symptoms probably have significant abnormalities that are observable on sinus radiographs. These radiographs provide noninvasive and rapid evaluation of the lower third of the nasal cavity and of the maxillary, frontal, sphenoid, and posterior ethmoid sinuses. Unfortunately, these views provide only limited information about anterior ethmoid anatomy and may be misleading in soft-tissue inflammatory disease; hence, more physicians are using CT for preoperative evaluation and MRI for excluding orbital and intracranial extension.[28, 31]

Unilateral sinus disease usually represents chronic inflammation but may be a sign of underlying malignancy, especially in individuals with a unilateral polyp.[32]

For more information, see the Medscape Reference article Imaging in Sinusitis.

Lund-Mackay scale for evaluation of images

Various staging systems have been proposed; however, no one system is accepted as the standard for use in chronic rhinosinusitis (CRS). Many studies use the Lund-Mackay scale to evaluate radiographic images. This scale grades the right and left sides independently, looking at the maxillary, anterior ethmoids, posterior ethmoids, sphenoid, and frontal sinuses, as well as the ostiomeatal complex. Each sinus is scored a 0 (no abnormality), 1 (partial opacification), or 2 (total opacification), while the ostiomeatal complex is scored either a 0 or 2 (for presence or absence of disease). Scores range from 0-24.

Cultures

Establishing the presence of sinus infection requires obtaining bacterial and fungal cultures. These can be obtained directly from the sinus cavity (by maxillary sinus tap or during surgery) or endoscopically from the ostia. Studies of chronic sinusitis have demonstrated no correlation between nasal flora and culture from the sinuses. Nasal swab cultures have therefore no diagnostic value. In severe cases, blood cultures, including fungal blood cultures, may be helpful.

Maxillary sinus tap

Traditionally, maxillary sinus tap via inferior meatal puncture was performed for sinus culture. Many otolaryngologists have moved away from maxillary sinus tap because of the discomfort of the procedure and the understanding that a culture of an organism from the middle meatus may be more accurate to determine the bacteria involved in the disease process.

Endoscopically directed middle meatal culture

Recent literature has supported the use of endoscopically directed culture of the middle meatus (the primary drainage system of the anterior ethmoid, maxillary, and frontal sinuses) with the use of either a suction trap or a swab. Endoscopically directed middle meatal cultures had a sensitivity of 80.9% and a specificity of 90.5% in a recent meta-analysis.[33]

Imaging Studies

Plain radiography may show mucosal thickenings or sinus opacities. However, it is not adequate to diagnose CRS because abnormalities detected on plain films are not sensitive or specific for sinusitis. Air fluid levels are uncommon in chronic sinusitis. Ethmoid sinuses and the ostiomeatal complex are not visualized well on plain sinus radiography. For more information, see the Medscape Reference article Imaging in Sinusitis.

Multiplanar sinus CT scan is the preferred imaging technique for evaluating CRS. Sinusitis is characterized by the presence of sinus mucosal thickening, sinus ostial obstruction, and sinus opacification. Other findings include polyps, mucoceles, and bony changes due to CRS (sclerosis, septations, erosions, and bowing).

Contrast-enhanced CT scanning is the current radiologic criterion standard for the evaluation of sinus diseases, although performing CT scanning in all patients with chronic sinus disease may be prohibitively expensive or medically unnecessary. CT scans are usually indicated after failure of maximal medical therapy, before surgical planning for evaluation of suspected complications, and when a neoplasm is a possibility. CT scan combined with endoscopic examination helps the surgeon to make operative decisions.

Coronal CT scan of the sinus correlates best with the surgical approach, permitting visualization of the anatomy of the nasal cavity, ostiomeatal complex, sinus cavities, and surrounding structures such as the orbit, cribriform plate, and optic canal. Anatomic obstructions at the ostiomeatal complex and dental pathologies are visualized well. Specific entities in the sinus cavity, such as aspergilloma, are also visualized well.

Most centers now offer limited sinus CT scans that consist of 5-12 coronal cuts. These limited or screening CT scans cost about the same as a plain radiography but provide more information.

Magnetic resonance imaging (MRI) is generally reserved only for complex cases. Soft-tissue contrast is better with MRI. Neoplasms, orbital and intracranial complications, and fungal sinusitis can be better evaluated with MRI.

Biopsy

Biopsy samples from the maxillary sinus mucosa of patients with chronic sinusitis show basement membrane thickening, atypical gland formation, goblet cell hyperplasia, mononuclear cell infiltration, and subepithelial edema. The mononuclear cell infiltrate often predominantly demonstrates neutrophils in acute disease and eosinophils in chronic disease. Rarely, squamous cell metaplasia may be seen.

Brush biopsy or turbinate biopsy

Evaluation of cilia function with a brush biopsy or turbinate biopsy can be considered in cases of presumed cilia dysfunction.

Endoscopic biopsy

Specimens obtained from sinus openings via endoscopy correlate well with those obtained with endoscopic surgery or sinus puncture. These should be processed for cultivation of aerobic and anaerobic bacteria, as well as fungi. Specimens evaluated for anaerobic bacteria should be sent in proper transport media. Liquid specimens are preferred to swab specimens.

Other Tests

Environmental allergen evaluation should be considered. Radioallergosorbent assay test (RAST) or skin testing for allergens may play an important role in treating patients with chronic rhinosinusitis (CRS) and confounding allergies. Perform allergy testing if allergy is thought to be the underlying cause.

Associated immune deficiency is evaluated with serum immunoglobulin and IgG subclass determination, antibody response to specific antigens, and HIV antibody testing (when indicated).[10]

A sweat test for cystic fibrosis should be considered in all children with nasal polyposis and CRS.

Total immunoglobulin E (IgE) levels, as well as the degree of staining of IgE in sinus epithelium and subepithelium, can be tested and may be helpful to evaluate for allergic fungal sinusitis.[34]

Approach Considerations

The goals of medical therapy for chronic rhinosinusitis (CRS) are to reduce mucosal edema, promote sinus drainage, and eradicate infections that may be present. This often requires a combination of topical or oral glucocorticoids, antibiotics, and nasal saline irrigation. If these measures fail, the patient should be referred to an otolaryngologist for consideration of sinus surgery. The role of bacteria in the pathogenesis of chronic sinusitis remains debatable; however, an early diagnosis and intensive treatment with oral antibiotics, topical nasal steroids, decongestants, and saline nasal sprays results in symptom relief in a significant number of patients, many of whom can be cured. When medical therapy is unsuccessful, refer the patient for surgical evaluation.

Inpatient treatment of chronic sinusitis is indicated for patients with orbital and intracranial complications. Immunosuppressed patients and pediatric patients with chronic sinusitis may need inpatient care, depending on the severity of the disease.

The American Academy of Otolaryngology-Head and Neck Surgery Foundation has updated its clinical practice guidelines for the treatment of adult sinusitis.[35] The recommendations to clinicians are as follows:

Control of Predisposing Factors

Because chronic sinusitis has many risk factors and potential etiologies, apply a combined approach to control or modify these factors in the management of chronic sinusitis.

Viral upper respiratory tract infections

Reduce viral exposures by improved personal hygiene. The roles of zinc and vitamin C in the prevention of viral upper respiratory tract infection are controversial. On June 16, 2009, the US Food and Drug Administration (FDA) issued a public health advisory and notified consumers and health care providers to discontinue the use of intranasal zinc products.[36] The intranasal zinc products (Zicam Nasal Gel/Nasal Swab; Matrixx Initiatives) are herbal cold remedies that claim to reduce the duration and severity of cold symptoms and are sold without a prescription. The FDA received more than 130 reports of anosmia (ie, an inability to detect odors) associated with intranasal zinc. Many of the reports described the loss of smell with the first dose.

Environmental and allergic factors

Environmental factors and/or allergic factors may predispose some individuals to chronic sinusitis. Reduce exposure to dust, molds, cigarette smoke, and other environmental chemical irritants. For patients with confounding nasal allergy, other antiallergy therapies, including either oral or topical antihistamines, cromolyn, topical steroids, and immunotherapy, may reduce recurrences and symptoms of allergic rhinitis.

Smoking cessation likely plays a large role in the success of both medical and surgical treatments because tobacco products act as an irritant to normal nasal mucosa and cilia function.

Gastroesophageal reflux disease

Patients with adult chronic sinusitis may benefit from control of gastroesophageal reflux disease (GERD), which has increasingly been implicated in causing or exacerbating respiratory ailments such as asthma and chronic sinusitis. The exact relationships and mechanisms are presently a matter of speculation.

Immunodeficiency

Appropriate control of various congenital and acquired immunodeficiency states is necessary to cure chronic sinusitis.

Asthma

Especially for patients with co-existing asthma, leukotriene inhibitors may play a role.[37]

Symptomatic Treatment

Symptoms may be relieved with topical decongestants, topical steroids, antibiotics, nasal saline, topical cromolyn, or mucolytics.

Steam inhalation and nasal saline irrigation may help by moistening dry secretions, reducing mucosal edema, and reducing mucous viscosity. A recent review concluded that low-volume (5 mL) nebulized saline spray was not more beneficial than intranasal steroids. Larger volume (150 mL) was marginally more efficacious than placebo.[38]

Initial oral steroid therapy followed by topical steroid therapy was found to be more effective than topical steroid therapy alone in decreasing polyp size and improving olfaction in patients with CRS with at least moderate nasal polyposis.[39] The severity of all symptoms was lessened.[40]

In June 2019, the FDA approved dupilumab for the treatment of inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. Dupilumab is a humanized monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. Blocking the IL-4R-alpha subunit inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and IgE. Approval was supported by phase 3 clinical trials (eg, SINUS-24, SINUS-52) demonstrating significant improvement nasal congestion/obstruction, nasal polyps score, sinus opacification, and improvement in smell when added to standard-of-care mometasone furoate nasal spray compared with placebo plus mometasone.[41, 42, 43]

Catalano et al evaluated balloon dilation for the treatment of chronic frontal sinusitis in 20 patients with advanced sinus disease in whom medical therapy had failed and therefore required operative intervention. Preoperative and postoperative CT scans were compared. There were no significant complications from balloon dilation, and there was significant improvement in patients with certain subsets of CRS.[44]

To see complete information on Balloon Sinuplasty, please go to the main article by clicking here.

Antimicrobial Therapy

An adequate antibiotic trial in CRS usually consists of a minimum of 3-4 weeks of treatment, preferably culture directed. Oral antibiotic regimens are generally used to treat chronic sinusitis, since this condition is primarily treated in an outpatient setting. For resistant cases, there may be a role for intravenous antibiotic therapy.

Initial choice of the appropriate antimicrobial(s) is usually empiric. Sinus cultures are not generally obtained for community-acquired infections unless empiric therapy fails to elicit a response. The agent(s) chosen should be effective against the most likely bacterial etiologies, including both aerobic and anaerobic pathogens. The likelihood of involvement by beta-lactamase–producing organisms should be considered. If methicillin-resistant Staphylococcus aureus (MRSA) is a possible pathogen, coverage for this should be included. History of drug allergies (if any) and cost of therapy should be taken into account as well. In addition, if the patient has received antibiotics during the preceding 3 months, a different class of antibiotics should be used.

Therapeutic regimens include the combination of a penicillin (eg, amoxicillin) plus a beta-lactamase inhibitor (eg, clavulanic acid), a combination of metronidazole plus a macrolide or a second- or third-generation cephalosporin, and the newer quinolones (eg, moxifloxacin). All of these agents (or similar ones) are available in oral and parenteral forms. Other effective antimicrobials are available only in parenteral form (eg, cefoxitin, cefotetan). If aerobic gram-negative organisms (eg, Pseudomonas aeruginosa) are involved, parenteral therapy with an aminoglycoside, a fourth-generation cephalosporin (cefepime or ceftazidime), or oral or parenteral treatment with a fluoroquinolone (only in postpubertal patients) is added. Parenteral therapy with a carbapenem (ie, imipenem, meropenem) is more expensive but provides coverage for most potential pathogens, both anaerobes and aerobes.

Agents that provide coverage for MRSA should be administered. Some options include tetracyclines, trimethoprim-sulfamethoxazole or linezolid, which are added to other regimens that cover anaerobes. Parenteral antimicrobials effective against MRSA include vancomycin, linezolid, and daptomycin. Biologics have shown promise in the treatment of refractory sinusitis.[45]

Ferguson et al performed a prospective observational study of 125 adults with classic symptoms of CRS who underwent nasal endoscopy and sinus CT. Severe symptoms occurred more often in younger patients with normal CT scans of the sinus than in those with positive CT findings. Improvement in response to antibiotics was similar for patients with positive CT findings and those with normal CT scans. The authors concluded that most symptoms considered to be typical for CRS proved to be nonspecific, and they suggest that objective evidence of mucopurulence assessed by endoscopy or CT should be obtained if a prolonged course of antibiotics is being considered.[46] Overall, there is little concrete evidence that systemic antibiotic therapy offers much improvement in the quality of life among adults with chronic sinusitis without polyps.[47]

It is useful to tailor therapy to the clinical type of CRS.[48] CRS without nasal polyps is treated with prednisone 20-40 mg daily tapered over 10 days plus an intranasal steroid. Antibiotic therapy is often required for up to 6 weeks or longer and should not be discontinued until the patient is asymptomatic. Discontinuation of antimicrobial therapy prior to complete resolution increases the likelihood of relapse.

Nebulized antibiotics and antifungal agents be used in refractory cases, especially in patients who have undergone sinus surgery and as a means to avoid prolonged therapy with intravenous antibiotics. Further studies need to be done to establish their role in treating CRS.[49, 50]

In individuals with CRS with nasal polyps, the major intervention is to relieve the obstruction to sinus drainage by reducing or eliminating the polyp. This is achieved primarily with glucocorticosteroids, both systemically and intranasally. Antileukotriene agents can be adjunctive to the effect of the steroids, especially in patients with asthma or an allergy to aspirin.[51]

There is a high rate of S aureus colonization of the sinus mucosa in CRS with nasal polyps. Three weeks of doxycycline therapy has been demonstrated to reduce polyp size, possibly because of the anti-inflammatory properties of the tetracyclines, as well as their anti-staphylococcal effects.[52]

Failure to relieve the polyposis obstruction with medical therapy is an indication for a surgical approach.

A 2015 study indicates that there is little difference in clinical outcomes between 3 weeks versus 6 weeks of antibiotic therapy for CRS.[53] This conclusion is contrary to the experience of many practitioners. At minimum, 3 weeks of antibiotic therapy could be used as a benchmark to reevaluate whether the patient has adequately responded. If not, a surgical approach may be considered.

The role of nebulized antibiotics and antifungal agents in treating refractory cases, especially in patients who have undergone sinus surgery, is very limited and generally should be avoided.[49] Fungal CRP is primarily treated with appropriate surgery.[35]

Difficult-to-treat chronic sinusitis is associated with nasal polyps, asthma, and aspirin-exacerbated respiratory disease.[54]

In summary, daily saline irrigation with topical cortical steroid therapy is to be considered prime therapy for chronic sinusitis. In patients with nasal polyposis, systemic corticosteroids (3 weeks), doxycycline (3 weeks), and/or a leukotriene antagonist should be considered. In patients without nasal polyps, 3 months of a macrolide antibiotic may be useful.[55]

Surgical Care

Functional Endoscopic Sinus Surgery

Surgical care is used as an adjunct to medical treatment in some cases. Surgical care is usually reserved for cases that are refractory to medical treatment and for patients with anatomic obstruction. Preoperative CT findings prior to sinus surgery may be poor predictors of surgical outcomes.[56]

The goal in surgical treatment is to reestablish sinus ventilation and to correct mucosal opposition in order to restore the mucociliary clearance system. Surgery strives to restore the functional integrity of the inflamed mucosal lining.

Recent advances in endoscopic technology and a better understanding of the importance of the ostiomeatal complex in the pathophysiology of sinusitis have led to the establishment of functional endoscopic sinus surgery (FESS) as the surgical procedure of choice for the treatment of chronic sinusitis.[57]

FESS facilitates the removal of disease in key areas, restores adequate aeration and drainage of the sinuses by establishing patency of the ostiomeatal complex, debulks severe polyposis, and causes less damage to normal nasal functioning. FESS is successful in restoring sinus health, with complete or at least moderate relief of symptoms in 80-90% of patients. Supportive medical treatment is instituted preoperatively and postoperatively. In children, surgical management is not as well established and should be reserved for complicated cases.

Occupational exposure may affect FESS outcomes. Symptoms may persist with work-related exposure to inhaled agents, and revision surgery may be required.[58]

In patients who have undergone endoscopic sinus surgery, total and direct healthcare costs, antibiotic usage, and the total number of imaging studies performed decreased after surgery for at least 3 years. However, the use of oral corticosteroids did not change.[59]

For more information, see the Medscape Reference article Functional Endoscopic Sinus Surgery.

Balloon Sinuplasty

Balloon sinuplasty is an option in the treatment of sinusitis that has failed to respond to appropriate medical therapy. Evidence is best for limited disease in patients with chronic rhinosinusitis without nasal polyposis affecting the frontal, sphenoid, and maxillary sinuses. Because it can be performed in an office setting, it can be a viable therapeutic alternative in patients with comorbidities who are unable to tolerate general anesthesia.[60]

Management of Chronic Maxillary Sinusitis

Three main surgical options are available for chronic maxillary sinusitis:

Management of Fungal Sinusitis

The preferred treatment for chronic fungal sinusitis is surgical debridement. Mycetomas or fungus balls are best treated by means of surgical removal. Allergic fungal sinusitis, which usually manifests as nasal polyps and allergic sinusitis, is treated by means of systemic steroids and surgical removal of polyps and mucinous secretions. Prolonged postoperative tapering doses of prednisone and anterior nasal glucocorticoid steroids are indicated to suppress the symptoms of fungal CRS.[61]

Some literature has suggested that topical antifungals may have a role in the treatment of CRS[62] ; however, this treatment remains controversial, and other studies have not supported this approach. A recent assessment that included 6 studies (N = 380) showed no statistically significant benefit of topical or systemic antifungals over placebo for the treatment of CRS.[63] Head et al concluded uncertainty regarding whether topical or systemic antifungals affect patient outcomes in adults with chronic rhinosinusitis compared with placebo or no treatment.[64]

Dietary Measures

Garlic has an active ingredient (allyl thiosulfinate) that provides a short-term decongestant effect. Eating foods highly seasoned with garlic has been considered therapeutic. Chewing horseradish root is another home remedy reported by some patients as effective for clearing the sinuses, but no scientific data support this belief.

Complications

The most common complication of chronic sinusitis is superimposed acute sinusitis. In children, the presence of pus in the nasopharynx may cause adenoiditis, and a high percentage of such patients develop secondary serous or purulent otitis media. Dacryocystitis and laryngitis may also occur as complications of chronic sinusitis in children.

Patients should be urgently referred to an otolaryngologist when they manifest any of these signs and/or symptoms: double or reduced vision, proptosis, rapidly developing periorbital edema, ophthalmoplegia, focal neurologic signs, high fever, severe headache, meningeal irritation, or significant or recurrent nose bleeding.[25]

Orbital complications include preseptal cellulitis, subperiosteal abscess, orbital cellulitis, orbital abscess, and cavernous sinus thrombosis. Intracranial complications include meningitis, epidural abscess, subdural abscess, and brain abscess.[25]

Other complications include osteomyelitis and mucocele formation.

Some studies have suggested a higher incidence of complications associated with fungal sinusitis.[65, 66] Untreated chronic sinusitis can lead to life-threatening complications, as in patients with cystic fibrosis.[67]

Individuals with medically resistant CRS exhibit a higher rate of asthma development. Those who have undergone endoscopic surgery early in their course appear to have a decreased risk of asthma.[68]

Consultations

Persistent or recurrent episodes of sinusitis despite appropriate medical therapy necessitate referral to an otolaryngologist. Examination, including nasal endoscopy and CT scanning, is mandatory to exclude surgically amenable conditions.

A consult with an otolaryngologist should be considered when one of the following occurs:

Seek consultation with an ophthalmologist at the earliest suggestion of orbital involvement. Seek consultation with a dentist when an odontogenic infection is present or suspected.

Long-term Monitoring

Continued outpatient medical treatment with nasal decongestants and topical steroids is important even after surgical treatment.

Nasal douching may improve symptoms, particularly following surgical treatment. Steam inhalation may have a role to liquefy and soften crusts while moisturizing dry inflamed mucosa.

Nasal cavity irrigation using buffered normal saline may have a role in decreasing mucosal edema. Irrigation should be performed at least twice daily.

Patients with presumed allergic rhinitis in conjunction with chronic sinusitis may benefit from an evaluation by an otolaryngologist trained in otolaryngic allergy or an allergist/immunologist. In most instances, prick/puncture tests are performed to clarify the role of allergies.

Medication Summary

The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications. Agents used in the treatment of chronic sinusitis include antibiotics, decongestants, nasal saline sprays, mast cell stabilizers, and expectorants.[69]

In June 2019, the FDA approved dupilumab for treatment of inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. Approval was supported by phase 3 clinical trials (eg, SINUS-24, SINUS-52) demonstrating significant improvement nasal congestion/obstruction, nasal polyps score, sinus opacification, and improvement in smell when added to standard-of-care mometasone furoate nasal spray compared with placebo plus mometasone.[41, 42, 43]

Antibiotics Summary

Criteria of antibiotic selection for the treatment of chronic sinusitis include the following:

Ideally, direct antibiotics against the organism obtained from endoscopic sampling and based on microbial sensitivity testing. If the patient is ill, empiric antimicrobial therapy may be indicated, which should be comprehensive and cover all likely pathogens in the context of the clinical setting. Duration of antibiotics is not well established. An initial 2- to 4-week trial of antibiotics may be reasonable. A longer duration (up to 12 mo) may be needed in some cases. After surgical management for uncomplicated chronic sinusitis is completed, antibiotics are of unclear benefit. Invasion of bone or deep structures may require a prolonged antibiotic course.

Currently, first-line antibiotics for patients with chronic sinusitis include amoxicillin-clavulanate, second-generation cephalosporins, and erythromycin-sulfasoxazole. Beta-lactamase–mediated resistance to the early second-generation cephalosporins is high among strains of Haemophilus influenzae and Moraxella catarrhalis. Cefixime, a third-generation cephalosporin, may be selected for infections caused by H influenzae or M catarrhalis, but it has a poor spectrum of activity against Streptococcus pneumoniae. The newer-generation macrolides, clarithromycin and azithromycin, achieve excellent mucosal levels and should be considered in patients with penicillin allergies. Some recent studies suggest that macrolides may also have some anti-inflammatory effects. Clindamycin should be reserved for resistant S pneumoniae.

Antimicrobials effective against S aureus may also be needed. Whenever methicillin-resistant S aureus (MRSA) is present, vancomycin or linezolid should be administered.

Antibiotics can also be administered topically with or without a nebulizer. This mode of administration is used in patients who have had prior sinus surgery.[70] The antimicrobials used are mupirocin, gentamicin, or tobramycin.

Amoxicillin (Amoxil, Trimox, Biomox)

Clinical Context:  Amoxicillin interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria.

Amoxicillin and clavulanate (Augmentin)

Clinical Context:  This drug combination treats bacteria resistant to beta-lactam antibiotics.

Class Summary

The penicillins are bactericidal antibiotics that work against sensitive organisms at adequate concentrations and inhibit the biosynthesis of cell wall mucopeptide. Examples of penicillins include amoxicillin (Amoxil, Trimox, Moxatag) and combination products such as amoxicillin-clavulanate (Augmentin, Augmentin XR, Augmentin ES).

Cefuroxime (Ceftin)

Clinical Context:  Cefuroxime is a second-generation cephalosporin that maintains gram-positive activity of first-generation cephalosporins; it also adds activity against Proteus mirabilis, H influenzae, Escherichia coli, Klebsiella pneumoniae, and M catarrhalis. The condition of the patient, severity of infection, and susceptibility of the microorganism determine the proper dose and route of administration.

Cefixime (Suprax)

Clinical Context:  Cefixime is a third-generation cephalosporin that arrests bacterial cell wall synthesis and inhibits bacterial growth by binding to one or more of the penicillin-binding proteins.

Cefaclor (Ceclor)

Clinical Context:  Cefaclor is a second-generation cephalosporin indicated for the management of infections caused by susceptible mixed aerobic-anaerobic microorganisms.

Cefprozil

Clinical Context:  Cefprozil is a second-generation cephalosporin that binds to one or more of the penicillin-binding proteins, which, in turn, inhibits cell wall synthesis and results in bactericidal activity.

Cefpodoxime (Vantin)

Clinical Context:  Cefpodoxime is a third-generation cephalosporin indicated for the management of infections caused by susceptible mixed aerobic-anaerobic microorganisms.

Cefepime

Clinical Context:  Cefepime is a fourth-generation cephalosporin that has gram-negative coverage comparable to ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). Cefepime is a zwitter ion; it rapidly penetrates gram-negative cells.

Class Summary

Cephalosporins are structurally and pharmacologically related to penicillins. They inhibit bacterial cell wall synthesis, resulting in bactericidal activity. Cephalosporins are divided into first, second, third and fourth generation. First generation-cephalosporins have greater activity against gram-positive bacteria, and succeeding generations have increased activity against gram-negative bacteria and decreased activity against gram-positive bacteria.

Clarithromycin (Biaxin)

Clinical Context:  Clarithromycin is a semisynthetic macrolide antibiotic that reversibly binds to the P site of 50S the ribosomal subunit of susceptible organisms and may inhibit RNA-dependent protein synthesis by stimulating dissociation of peptidyl t-RNA from ribosomes, causing bacterial growth inhibition.

Azithromycin (Zithromax)

Clinical Context:  Azithromycin is an advanced-generation macrolide; it works similarly to clarithromycin but with a shorter dosage time.

Erythromycin base / sulfisoxazole

Clinical Context:  Erythromycin is a macrolide antibiotic with a large spectrum of activity. Erythromycin binds to the 50S ribosomal subunit of the bacteria, which inhibits protein synthesis. Sulfisoxazole expands erythromycin's coverage to include gram-negative bacteria. Sulfisoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid.

Class Summary

Macrolide antibiotics have bacteriostatic activity and exert their antibacterial action by binding to the 50S ribosomal subunit of susceptible organisms, resulting in inhibition of protein synthesis.

Levofloxacin (Levaquin)

Clinical Context:  Levofloxacin inhibits bacterial topoisomerase IV and DNA gyrase, which are required for bacterial DNA replication and transcription.

Moxifloxacin (Avelox)

Clinical Context:  Moxifloxacin inhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription.

Class Summary

Fluoroquinolones have broad-spectrum activity against gram-positive and gram-negative aerobic organisms. They inhibit DNA synthesis and growth by inhibiting DNA gyrase and topoisomerase, which is required for replication, transcription, and translation of genetic material.

Minocycline (Minocin, Dynacin, Solodyn)

Clinical Context:  For the treatment of infections caused by susceptible gram-negative and gram-positive organisms.

Doxycycline (Adoxa, Alodox, Doxy 100, Doryx, Vibramycin)

Clinical Context:  Doxycycline is a broad-spectrum, synthetically derived, bacteriostatic antibiotic in the tetracycline class. It is almost completely absorbed, concentrates in bile, and is excreted in urine and feces as a biologically active metabolite in high concentrations. The drug inhibits protein synthesis (and thus bacterial growth) by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Doxycycline may block dissociation of peptidyl transfer ribonucleic acid (t-RNA) from ribosomes, causing RNA-dependent protein synthesis to arrest.

Class Summary

Tetracyclines bind with the 30S and possibly 50S ribosomal subunits of susceptible bacteria to inhibit bacterial protein synthesis.

Vancomycin (Lyphocin, Vancocin, Vancoled)

Clinical Context:  Vancomycin is indicated for patients who have infections with resistant staphylococci. To avoid toxicity, the current recommendation is to assay vancomycin trough levels after the third dose is drawn 0.5 hour prior to next dosing. Use CrCl to adjust the dose in patients diagnosed with renal impairment. It is used in conjunction with gentamicin for prophylaxis in patients with penicillin allergy who are undergoing gastrointestinal or genitourinary procedures.

Metronidazole (Flagyl)

Clinical Context:  Metronidazole is an imidazole ring-based antibiotic that is active against various anaerobic bacteria and protozoa. It is used in combination with other antimicrobial agents (except C difficile enterocolitis).

Trimethoprim/sulfamethoxazole (Bactrim DS, Septra DS)

Clinical Context:  Trimethoprim-sulfamethoxazole inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. One double-strength tablet contains trimethoprim (TMP) 160 mg and sulfamethoxazole (SMX) 800 mg

Class Summary

Anti-infectives such as vancomycin, doxycycline/minocycline, metronidazole and sulfamethoxazole/trimethoprim are effective against some types of bacteria that have become resistant to other antibiotics.

Oxymetazoline (Afrin)

Clinical Context:  Oxymetazoline is applied directly to mucous membranes, where it stimulates alpha-adrenergic receptors and causes vasoconstriction. Decongestion occurs without drastic changes in blood pressure, vascular redistribution, or cardiac stimulation.

Naphazoline (Privine)

Clinical Context:  Naphazoline's alpha-adrenergic effects on arterioles of conjunctiva and nasal mucosa produce vasoconstriction.

Tetrahydrozoline, ophthalmic (Tyzine, Visine)

Clinical Context:  The alpha-adrenergic effects of tetrahydrozoline on nasal mucosa produce vasoconstriction.

Xylometazoline (Otrivin)

Clinical Context:  Xylometazoline is applied directly to mucous membranes, where it stimulates alpha-adrenergic receptors and causes vasoconstriction.

Phenylephrine (Neo-Synephrine)

Clinical Context:  Phenylephrine HCl is a synthetic sympathomimetic amine. It is a strong postsynaptic alpha-receptor stimulant with little beta-adrenergic activity that produces vasoconstriction of arterioles in the body.

Pseudoephedrine (Sudafed)

Clinical Context:  Pseudoephedrine stimulates vasoconstriction by directly activating the alpha-adrenergic receptors of the respiratory mucosa; it induces bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors. The drug is available in tabs, chewables, solution, extended-release tabs, and infant drops.

Class Summary

These agents are alpha-adrenergic agonists that act by constricting dilated mucosal vessels. Topical preparations of oxymetazoline, naphazoline, tetrahydrozoline, and xylometazoline are available. Use all adrenergic topical preparations with caution in young patients and the elderly population. Topical agents can produce rebound vasodilation on discontinuation and rhinitis medicamentosa on prolonged use. Both of these adverse effects respond well to topical steroids.[16]

Goals include reduction of tissue edema, facilitation of drainage, and maintenance of patency of sinus ostia. In short, decongestants are necessary to meet the management goals for chronic sinusitis. Decongestants are available in 2 forms, topical and oral. Each agent differs slightly in its method of action.

Topical agents are locally active vasoconstrictor agents such as phenylephrine HCl 0.5% and oxymetazoline HCl 0.5% that provide almost immediate symptomatic relief by shrinking the inflamed and swollen nasal mucosa. Topical nasal formulations should not be used for longer than 3-5 consecutive days because of the risk of development of tolerance, rhinitis medicamentosa, and rebound after drug withdrawal.

Oral systemic agents are used when decongestion is necessary for longer than 3 days. An oral systemic agent, such as phenylpropanolamine (recalled from US market) or pseudoephedrine, is preferred. Oral decongestants are alpha-adrenergic agonists that reduce nasal blood flow. Theoretically, these oral systemic agents have the potential to act on tissues deep in the ostiomeatal complex, where topical agents may not penetrate effectively.

Fluticasone propionate (Flonase)

Clinical Context:  Fluticasone propionate is applied as a nasal spray. It is particularly effective in allergic and vasomotor rhinosinusitis and rhinosinusitis medicamentosa. It is also used as prophylaxis for nasal polyps. Plasma concentrations are very low following intranasal administration in recommended doses.

Beclomethasone dipropionate (Beconase AQ)

Clinical Context:  Beclomethasone dipropionate is a topical steroid nasal spray. It acts locally as an anti-inflammatory and vasoconstrictor. The drug is readily absorbed through the nasopharyngeal mucosa and GI tract. It is useful in allergic and vasomotor rhinosinusitis and sinusitis medicamentosa.

Class Summary

These agents are particularly effective for chronic sinusitis associated with allergic rhinitis, nasal polyps, and rhinitis medicamentosa. Corticosteroids can be administered in the form of nasal sprays or solutions. Topical steroids along with systemic antibiotics are now the key components of the medical armamentarium in the management of chronic sinusitis. Oral glucocorticoids (eg, prednisone) may be prescribed to patients with chronic rhinosinusitis in allergic fungal rhinosinusitis, reducing the size of polyps, and refractory mucosal edema.

Saline nasal spray (Ayr, Ocean)

Clinical Context:  Saline nasal spray loosens mucous secretions to help remove mucus from the nose and sinuses.

Class Summary

Nasal saline spray, nasal irrigation, and steam inhalation help by moistening dry secretions, reducing mucosal edema, and reducing mucous viscosity. Symptomatic relief gained in some patients can be substantial; moreover, these are benign modalities of therapy. Nasal irrigation washes the nasal cavities, reduces postnasal drainage, removes secretions, and rinses allergens and irritants. The use of saline washes prior to administration of other intranasal medications enables the medication to affect the mucosa.

Cromolyn sodium (Nasalcrom)

Clinical Context:  Cromolyn sodium inhibits degranulation of sensitized mast cells following their exposure to specific antigens.

Class Summary

These agents may be helpful in chronic sinusitis associated with allergic rhinitis.

Guaifenesin (Humibid-LA)

Clinical Context:  Increases respiratory tract fluid secretions and helps to loosen phlegm and bronchial secretions. Indicated for patients with bronchiectasis complicated by tenacious mucous and/or mucous plugs.

Class Summary

Although no controlled studies on the efficacy of mucolytics in chronic sinusitis are available, guaifenesin (mucolytic agent) may be helpful in ameliorating some symptoms.

Montelukast (Singulair)

Clinical Context:  Montelukast selectively prevents the action of leukotrienes released by mast cells and eosinophils. Montelukast works to inhibit the effects of the leukotriene receptor that causes asthma, including airway edema, smooth muscle contraction, and cellular activity associated with the symptoms.

Zafirlukast (Accolate)

Clinical Context:  Zafirlukast selectively prevents the action of leukotrienes released by mast cells and eosinophils. It inhibits the effects by the leukotriene receptor, which has been associated with asthma, including airway edema, smooth muscle contraction, and cellular activity associated with the symptoms.

Class Summary

Leukotriene inhibitors may play a role especially in patients with coexisting asthma. Leukotrienes are products of arachidonic acid from mast cells and eosinophiles. They cause bronchial edema, smooth muscle contraction, and inflammation. A selective binding to the receptor occurs, preventing this reaction.

Dupilumab (Dupixent)

Clinical Context:  Monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. Blocking the IL-4R-alpha subunit inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and IgE. It is indicated for adults with inadequately controlled severe CRSwNP.

Class Summary

Inhibition of interleukins 4 and 13 with dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) has shown to decrease polyp burden and improve symptoms.[41, 42, 43]

What is chronic sinusitis?What are the signs and symptoms of chronic sinusitis?What are risk factors for chronic sinusitis?What is the goal of medical therapy for chronic sinusitis?What are the diagnostic criteria for chronic rhinosinusitis (CRS)?What anatomy knowledge is needed to understand the pathophysiology and management of chronic sinusitis?What triggers stasis of secretions inside the sinuses in chronic sinusitis?What is the pathophysiology of chronic sinusitis?What is the role of bacteria in the pathogenesis of chronic sinusitis?Which factors contribute to inflammation in chronic rhinosinusitis (CRS)?What is the etiology of chronic sinusitis?What is the role of bacterial infection in chronic sinusitis?What types of bacteria are involved in the etiology of chronic sinusitis?What is the role of fungal agents in the etiology of chronic sinusitis?What are the risk factors for chronic sinusitis?What is the prevalence of chronic sinusitis in the US?What is the global prevalence of chronic sinusitis?Why is rhinosinusitis more prevalent in children?What is the prognosis of chronic sinusitis?What is the role of medical history in the evaluation of chronic rhinosinusitis (CRS)?Which clinical history is characteristic of chronic sinusitis?What are the signs and symptoms of chronic sinusitis?Which clinical history is characteristic of chronic sinusitis in pediatric patients?What factors should the patient history of chronic sinusitis focus on?Which physical findings are characteristic of chronic sinusitis?How is tenderness or swelling assessed in chronic sinusitis?What is the role of an oropharynx exam in the evaluation of chronic sinusitis?What is the role of anterior rhinoscopy in the evaluation of chronic sinusitis?Which exams may be helpful supplements to the nasal exam for chronic sinusitis?What is the role of an ear exam for evaluation of chronic sinusitis?What are ophthalmic manifestations of chronic sinusitis?What is the role of laryngeal exam in the evaluation of chronic sinusitis?What is the role of cranial nerve exam in the evaluation of chronic sinusitis?Which physical findings are characteristic of chronic fungal sinusitis?What are the diagnostic criteria for chronic rhinosinusitis (CRS)?How and when were amendments made to the diagnostic criteria for chronic rhinosinusitis (CRS)?What is the role of imaging in the diagnosis of chronic sinusitis?How is chronic rhinosinusitis (CRS) defined?What are the potential serious complications of chronic sinusitis?Which conditions should be considered in the differential diagnosis of chronic sinusitis?What are the differential diagnoses for Chronic Sinusitis?What is included in the workup for chronic sinusitis?How is chronic rhinosinusitis (CRS) staged?How are cultures obtained for the workup of chronic sinusitis?What is the role of maxillary sinus tap in the workup of chronic sinusitis?What is the role of endoscopy in the workup of chronic sinusitis?What is the role of radiography in the workup of chronic sinusitis?What is the preferred imaging technique for evaluating chronic rhinosinusitis (CRS)?What is the role of contrast-enhanced CT in the evaluation of chronic sinusitis?When is coronal CT scanning indicated in the workup of chronic sinusitis?What is the role of MRI in the evaluation of chronic sinusitis?Which biopsy findings are characteristic of chronic sinusitis?What is the indication for a brush or turbinate biopsy in the workup of chronic sinusitis?What is the indication for an endoscopic biopsy in the workup of chronic sinusitis?Which supplemental tests may be indicated in the workup of chronic sinusitis?What are the goals of medical therapy for chronic rhinosinusitis (CRS)?When is inpatient treatment indicated for chronic sinusitis?What are the AAO-HNSF treatment guidelines for adult chronic sinusitis?How are the predisposing factors managed in chronic sinusitis?What is the role of zinc in the prevention of chronic sinusitis?How are environmental and allergic risk factors managed to prevent chronic sinusitis?What is the role of gastroesophageal reflux disease (GERD) in chronic sinusitis?What is necessary to cure chronic sinusitis?What is the role of leukotriene inhibitors in chronic sinusitis?What is the symptomatic treatment of chronic sinusitis?What is the role of antibiotics in the treatment of chronic rhinosinusitis (CRS)?What is the initial choice for antimicrobials in the treatment of chronic sinusitis?What are the therapeutic antimicrobial regimens used to treat chronic sinusitis?What is the efficacy of systemic antibiotic therapy for chronic sinusitis?What are the treatment options for chronic rhinosinusitis (CRS)?What is the optimal duration of antibiotic therapy for chronic rhinosinusitis (CRS)?What is the role of nebulized antibiotics and antifungal agents in the treatment of chronic sinusitis?Which factors increase the likelihood of difficult-to-treat chronic sinusitis?What is the prime therapy for chronic sinusitis?When is surgery indicated in the treatment of chronic sinusitis?What is the goal of surgery for chronic sinusitis?What is the surgical procedure of choice for the treatment of chronic sinusitis?What are the surgical options for chronic maxillary sinusitis?What is the treatment of choice for chronic fungal sinusitis?Which dietary measures may be helpful in the treatment of chronic sinusitis?What is the most common complication of chronic sinusitis?When should patients with chronic sinusitis be referred to an otolaryngologist?What are orbital complications in chronic sinusitis?What can result from untreated chronic sinusitis?Which health risk is increased with medically-resistant chronic rhinosinusitis (CRS)?When should patients with chronic sinusitis be referred to an otolaryngologist?When should patients with chronic sinusitis be referred to an ophthalmologist?What long-term monitoring is needed for chronic sinusitis?What are the goals of drug treatment for chronic sinusitis?What are the criteria for antibiotic selection for the treatment of chronic sinusitis?How are antibiotics administered for the treatment of chronic sinusitis?What are the first-line antibiotics for treatment of chronic sinusitis?Which medications in the drug class Leukotriene Receptor Antagonist are used in the treatment of Chronic Sinusitis?Which medications in the drug class Expectorants are used in the treatment of Chronic Sinusitis?Which medications in the drug class Mast cell stabilizers are used in the treatment of Chronic Sinusitis?Which medications in the drug class Nasal sprays are used in the treatment of Chronic Sinusitis?Which medications in the drug class Corticosteroids are used in the treatment of Chronic Sinusitis?Which medications in the drug class Decongestants are used in the treatment of Chronic Sinusitis?Which medications in the drug class Anti-Infectives are used in the treatment of Chronic Sinusitis?Which medications in the drug class Tetracyclines are used in the treatment of Chronic Sinusitis?Which medications in the drug class Fluoroquinolones are used in the treatment of Chronic Sinusitis?Which medications in the drug class Macrolides are used in the treatment of Chronic Sinusitis?Which medications in the drug class Cephalosporins are used in the treatment of Chronic Sinusitis?Which medications in the drug class Penicillins are used in the treatment of Chronic Sinusitis?Which medications in the drug class Interleukin Inhibitors are used in the treatment of Chronic Sinusitis?

Author

Itzhak Brook, MD, MSc, Professor, Department of Pediatrics, Georgetown University School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Daniel R Hinthorn, MD, FACP, Vice Chair of Internal Medicine, Professor of Internal Medicine, Pediatrics (Hon), and Family Medicine (Hon), Director, Division of Infectious Diseases, University of Kansas Medical Center

Disclosure: Nothing to disclose.

Chief Editor

John L Brusch, MD, FACP, Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

Disclosure: Nothing to disclose.

Acknowledgements

Osama A Abdel Razek, MD, MBBCh, MSc Lecturer in ENT, Suez Canal University Medical School, Egypt

Disclosure: Nothing to disclose.

Himal Bajracharya, MBBS Assistant Professor, Department of Internal Medicine, Division of Infectious Diseases, Kansas University Medical Center

Disclosure: Nothing to disclose.

Kenneth C Earhart, MD Deputy Head, Disease Surveillance Program, United States Naval Medical Research Unit #3

Kenneth C Earhart, MD, is a member of the following medical societies: American College of Physicians, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Undersea and Hyperbaric Medical Society

Disclosure: Nothing to disclose.

Marvin P Fried, MD, FACS Professor and University Chairman, Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center, Albert Einstein College of Medicine

Marvin P Fried, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American Bronchoesophagological Association, American College of Surgeons, American Laryngological Association, American Laryngological Rhinological and Otological Society, American Medical Association, American Rhinologic Society, American Society for Head and Neck Surgery, American Society for Laser Medicineand Surgery, American Society of Plastic and Reconstructive Surgery, Massachusetts Medical Society, Phi Beta Kappa, and Society of University Otolaryngologists-Head and Neck Surgeons

Disclosure: Medtronic Consulting fee Consulting; MiMosa Consulting fee Board membership

Babak Sadoughi, MD Fellow in Laryngology/Neurolaryngology, New York Center for Voice and Swallowing Disorders, St Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons

Babak Sadoughi, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, Association for Research in Otolaryngology, and Medical Society of the State of New York

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Gordon L Woods, MD Consulting Staff, Department of Internal Medicine, University Medical Center

Gordon L Woods, MD, is a member of the following medical societies: Society of General Internal Medicine

Disclosure: Nothing to disclose.

References

  1. American Academy of Pediatrics - Subcommittee on Management of Sinusitis and Committee on Quality Management. Clinical practice guideline: management of sinusitis. Pediatrics. 2001 Sep. 108(3):798-808. [View Abstract]
  2. Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol. 2005 Dec. 116(6 Suppl):S13-47. [View Abstract]
  3. Report of the Rhinosinusitis Task Force Committee Meeting. Alexandria, Virginia, August 17, 1996. Otolaryngol Head Neck Surg. 1997 Sep. 117(3 Pt 2):S1-68. [View Abstract]
  4. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003 Sep. 129(3 Suppl):S1-32. [View Abstract]
  5. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol. 2004 Dec. 114(6 Suppl):155-212. [View Abstract]
  6. Biel MA, Brown CA, Levinson RM, Garvis GE, Paisner HM, Sigel ME, et al. Evaluation of the microbiology of chronic maxillary sinusitis. Ann Otol Rhinol Laryngol. 1998 Nov. 107(11 Pt 1):942-5. [View Abstract]
  7. Brook I, Frazier EH, Foote PA. Microbiology of the transition from acute to chronic maxillary sinusitis. J Med Microbiol. 1996 Nov. 45(5):372-5. [View Abstract]
  8. Ramakrishnan Y, Shields RC, Elbadawey MR, Wilson JA. Biofilms in chronic rhinosinusitis: what is new and where next?. J Laryngol Otol. 2015 Aug. 129 (8):744-51. [View Abstract]
  9. Nayak N, Satpathy G, Prasad S, Thakar A, Chandra M, Nag TC. Clinical implications of microbial biofilms in chronic rhinosinusitis and orbital cellulitis. BMC Ophthalmol. 2016 Sep 21. 16 (1):165. [View Abstract]
  10. Mazza JM, Lin SY. Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review. Int Forum Allergy Rhinol. 2016 Oct. 6 (10):1029-1033. [View Abstract]
  11. Fastenberg JH, Hsueh WD, Mustafa A, Akbar NA, Abuzeid WM. Biofilms in chronic rhinosinusitis: Pathophysiology and therapeutic strategies. World J Otorhinolaryngol Head Neck Surg. 2016 Dec. 2 (4):219-229. [View Abstract]
  12. Brook I, Foote PA, Hausfeld JN. Increase in the frequency of recovery of meticillin-resistant Staphylococcus aureus in acute and chronic maxillary sinusitis. J Med Microbiol. 2008 Aug. 57:1015-7. [View Abstract]
  13. Brook I. Acute and chronic bacterial sinusitis. Infect Dis Clin North Am. 2007 Jun. 21(2):427-48, vii. [View Abstract]
  14. Brook I. Bacteriology of chronic maxillary sinusitis in adults. Ann Otol Rhinol Laryngol. 1989 Jun. 98(6):426-8. [View Abstract]
  15. Brook I. Microbiology and choice of antimicrobial therapy for acute sinusitis complicated by subperiosteal abscess in children. Int J Pediatr Otorhinolaryngol. 2016 May. 84:21-6. [View Abstract]
  16. Incorvaia C, Leo G. Treatment of rhinosinusitis: other medical options. Int J Immunopathol Pharmacol. 2010 Jan-Mar. 23(1 Suppl):70-3. [View Abstract]
  17. Brook I, Yocum P. Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with chronic maxillary sinusitis. Ann Otol Rhinol Laryngol. 1999 Mar. 108(3):293-5. [View Abstract]
  18. Brook I, Foote PA, Frazier EH. Microbiology of acute exacerbation of chronic sinusitis. Laryngoscope. 2004. 114:129-31.
  19. Vickery TW, Ramakrishnan VR, Suh JD. The Role of Staphylococcus aureus in Patients with Chronic Sinusitis and Nasal Polyposis. Curr Allergy Asthma Rep. 2019 Mar 11. 19 (4):21. [View Abstract]
  20. Nadel DM, Lanza DC, Kennedy DW. Endoscopically guided cultures in chronic sinusitis. Am J Rhinol. 1998 Jul-Aug. 12(4):233-41. [View Abstract]
  21. Ferguson BJ. Definitions of fungal rhinosinusitis. Otolaryngol Clin North Am. 2000 Apr. 33(2):227-35. [View Abstract]
  22. Marcus S, Roland LT, DelGaudio JM, Wise SK. The relationship between allergy and chronic rhinosinusitis. Laryngoscope Investig Otolaryngol. 2019 Feb. 4 (1):13-17. [View Abstract]
  23. Pleis JR, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2007. Vital Health Stat 10. 2009 May. 1-159. [View Abstract]
  24. Shah AR, Hairston JA, Tami TA. Sinusitis in HIV: microbiology and therapy. Curr Allergy Asthma Rep. 2005 Nov. 5(6):495-9. [View Abstract]
  25. Brook I. Microbiology and antimicrobial treatment of orbital and intracranial complications of sinusitis in children and their management. Int J Pediatr Otorhinolaryngol. 2009 Sep. 73(9):1183-6. [View Abstract]
  26. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012 Mar. 50 (1):1-12. [View Abstract]
  27. Chakrabarti A, Denning DW, Ferguson BJ, et al. Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope. 2009 Sep. 119(9):1809-18. [View Abstract]
  28. Manes RP, Batra PS. Etiology, diagnosis and management of chronic rhinosinusitis. Expert Rev Anti Infect Ther. 2013 Jan. 11(1):25-35. [View Abstract]
  29. [Guideline] Rosenfeld RM,Piccirillo JF, Chandrasekhar SS,et al. of. Clinical practice guideline (update) on adult sinusitis. J Otolaryngol Head Neck Surg. 2015. 152(2 suppl):S1-S39. [View Abstract]
  30. Ziegler A, Patadia M, Stankiewicz J. Neurological Complications of Acute and Chronic Sinusitis. Curr Neurol Neurosci Rep. 2018 Feb 5. 18 (2):5. [View Abstract]
  31. Joshi VM, Sansi R. Imaging in Sinonasal Inflammatory Disease. Neuroimaging Clin N Am. 2015 Nov. 25 (4):549-68. [View Abstract]
  32. Paz Silva M, Pinto JM, Corey JP, Mhoon EE, Baroody FM, Naclerio RM. Diagnostic algorithm for unilateral sinus disease: a 15-year retrospective review. Int Forum Allergy Rhinol. 2015 Jul. 5 (7):590-6. [View Abstract]
  33. Benninger MS, Payne SC, Ferguson BJ, Hadley JA, Ahmad N. Endoscopically directed middle meatal cultures versus maxillary sinus taps in acute bacterial maxillary rhinosinusitis: a meta-analysis. Otolaryngol Head Neck Surg. 2006 Jan. 134(1):3-9. [View Abstract]
  34. Wise SK, Ahn CN, Lathers DM, Mulligan RM, Schlosser RJ. Antigen-specific IgE in sinus mucosa of allergic fungal rhinosinusitis patients. Am J Rhinol. 2008 Sep-Oct. 22(5):451-6. [View Abstract]
  35. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015 Apr. 152 (2 Suppl):S1-S39. [View Abstract]
  36. United States Food and Drug Administration. Zicam cold remedy nasal products (Cold Remedy Nasal Gel, Cold Remedy Nasal Swabs, and Cold Remedy Saws, Kids Size). MedWatch Public Health Advisory. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166996.htm. Accessed: June 16, 2009.
  37. Massoth L, Anderson C, McKinney KA. Asthma and Chronic Rhinosinusitis: Diagnosis and Medical Management. Med Sci (Basel). 2019 Mar 27. 7 (4):[View Abstract]
  38. Chong LY, Head K, Hopkins C, Philpott C, Glew S, Scadding G, et al. Saline irrigation for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26. 4:CD011995. [View Abstract]
  39. Vaidyanathan S, Barnes M, Williamson P, Hopkinson P, Donnan PT, Lipworth B. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med. 2011 Mar 1. 154(5):293-302. [View Abstract]
  40. Chong LY, Head K, Hopkins C, Philpott C, Schilder AG, Burton MJ. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26. 4:CD011996. [View Abstract]
  41. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016 Feb 2. 315 (5):469-79. [View Abstract]
  42. Han JK, Bachert C, et al. Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: Results from the randomized phase 3 Sinus-24 study (abstract 422). J Aller Clin Immunol. 2019 Feb;143(2; suppl). Presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI); San Francisco, CA; February 23, 2019.
  43. Bachert C, et al. A randomized phase 3 study, SINUS-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis (abstract L36). Presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI); San Francisco, CA; February 25, 2019.
  44. Catalano PJ, Payne SC. Balloon dilation of the frontal recess in patients with chronic frontal sinusitis and advanced sinus disease: an initial report. Ann Otol Rhinol Laryngol. 2009 Feb. 118(2):107-12. [View Abstract]
  45. Schwartz JS, Tajudeen BA, Cohen NA. Medical management of chronic rhinosinusitis - a review of traditional and novel medical therapies. Expert Opin Investig Drugs. 2017 Oct. 26 (10):1123-1130. [View Abstract]
  46. Ferguson BJ, Narita M, Yu VL, Wagener MM, Gwaltney JM Jr. Prospective observational study of chronic rhinosinusitis: environmental triggers and antibiotic implications. Clin Infect Dis. 2012 Jan. 54(1):62-8. [View Abstract]
  47. Head K, Chong LY, Piromchai P, Hopkins C, Philpott C, Schilder AG, et al. Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26. 4:CD011994. [View Abstract]
  48. Piromchai P, Thanaviratananich S, Laopaiboon M. Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults. Cochrane Database Syst Rev. 2011 May 11. CD008233. [View Abstract]
  49. Lim M, Citardi MJ, Leong JL. Topical antimicrobials in the management of chronic rhinosinusitis: a systematic review. Am J Rhinol. 2008 Jul-Aug. 22(4):381-9. [View Abstract]
  50. Reychler G, Domachowski C, Latiers AC, Jamar F, Rombaux P. Clinical efficacy of intranasal drug delivery by nebulization in chronic rhinosinusitis: a systematic review. Rhinology. 2019 Apr 1. 57 (2):82-93. [View Abstract]
  51. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001 Sep. 31(9):1385-91. [View Abstract]
  52. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010 May. 125(5):1069-1076.e4. [View Abstract]
  53. Sreenath SB, Taylor RJ, Miller JD, Ambrose EC, Rawal RB, Ebert CS Jr, et al. A prospective randomized cohort study evaluating 3 weeks vs 6 weeks of oral antibiotic treatment in the setting of "maximal medical therapy" for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015 May 23. [View Abstract]
  54. López-Chacón M, Mullol J, Pujols L. Clinical and biological markers of difficult-to-treat severe chronic rhinosinusitis. Curr Allergy Asthma Rep. 2015 May. 15 (5):19. [View Abstract]
  55. Rudmik L, Soler ZM. Medical Therapies for Adult Chronic Sinusitis: A Systematic Review. JAMA. 2015 Sep 1. 314 (9):926-39. [View Abstract]
  56. Bhattacharyya N. Radiographic stage fails to predict symptom outcomes after endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope. 2006 Jan. 116(1):18-22. [View Abstract]
  57. Welch KC, Stankiewicz JA. A contemporary review of endoscopic sinus surgery: techniques, tools, and outcomes. Laryngoscope. 2009 Nov. 119(11):2258-68. [View Abstract]
  58. Hox V, Delrue S, Scheers H, Adams E, Keirsbilck S, Jorissen M, et al. Negative impact of occupational exposure on surgical outcome in patients with rhinosinusitis. Allergy. 2012 Jan 9. [View Abstract]
  59. Purcell PL, Beck S, Davis GE. The impact of endoscopic sinus surgery on total direct healthcare costs among patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015 Jun. 5 (6):498-505. [View Abstract]
  60. Cingi C, Bayar Muluk N, Lee JT. Current indications for balloon sinuplasty. Curr Opin Otolaryngol Head Neck Surg. 2019 Feb. 27 (1):7-13. [View Abstract]
  61. Singh V. Fungal Rhinosinusitis: Unravelling the Disease Spectrum. J Maxillofac Oral Surg. 2019 Jun. 18 (2):164-179. [View Abstract]
  62. Ponikau JU, Sherris DA, Weaver A, Kita H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol. 2005 Jan. 115(1):125-31. [View Abstract]
  63. Sacks PL, Harvey RJ, Rimmer J, Gallagher RM, Sacks R. Topical and systemic antifungal therapy for the symptomatic treatment of chronic rhinosinusitis. Cochrane Database Syst Rev. 2011 Aug 10. CD008263. [View Abstract]
  64. Head K, Sharp S, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database Syst Rev. 2018 Sep 10. 9:CD012453. [View Abstract]
  65. Gupta AK, Bansal S, Gupta A, Mathur N. Is fungal infestation of paranasal sinuses more aggressive in pediatric population?. Int J Pediatr Otorhinolaryngol. 2006 Apr. 70(4):603-8. [View Abstract]
  66. Hakim HE, Malik AC, Aronyk K, Ledi E, Bhargava R. The prevalence of intracranial complications in pediatric frontal sinusitis. Int J Pediatr Otorhinolaryngol. 2006 Aug. 70(8):1383-7. [View Abstract]
  67. Sharma GD, Doershuk CF, Stern RC. Erosion of the wall of the frontal sinus caused by mucopyocele in cystic fibrosis. J Pediatr. 1994 May. 124(5 Pt 1):745-7. [View Abstract]
  68. Benninger MS, Sindwani R, Holy CE, Hopkins C. Impact of medically recalcitrant chronic rhinosinusitis on incidence of asthma. Int Forum Allergy Rhinol. 2016 Feb. 6 (2):124-9. [View Abstract]
  69. Brook I. Treatment modalities for bacterial rhinosinusitis. Expert Opin Pharmacother. 2010 Apr. 11(5):755-69. [View Abstract]
  70. Huang A, Govindaraj S. Topical therapy in the management of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2013 Feb. 21(1):31-8. [View Abstract]

Endoscopic view right nasal cavity; lacrimal bone (L), uncinate process (U), ethmoid bulla (B), middle turbinate (MT), nasal septum (S).

Endoscopic view right nasal cavity; lacrimal bone (L), uncinate process (U), ethmoid bulla (B), middle turbinate (MT), nasal septum (S).

Air-fluid level (arrow) in the maxillary sinus suggests sinusitis.